213 related articles for article (PubMed ID: 20444856)
1. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.
Verstappen SM; Watson KD; Lunt M; McGrother K; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2010 Aug; 49(8):1570-7. PubMed ID: 20444856
[TBL] [Abstract][Full Text] [Related]
2. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
3. Determinants associated with work participation in patients with established rheumatoid arthritis taking tumor necrosis factor inhibitors.
Manders SH; Kievit W; Braakman-Jansen AL; Brus HL; Hendriks L; Fransen J; van de Laar MA; van Riel PL
J Rheumatol; 2014 Jul; 41(7):1263-9. PubMed ID: 24833758
[TBL] [Abstract][Full Text] [Related]
4. Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work?
Olofsson T; Petersson IF; Eriksson JK; Englund M; Nilsson JA; Geborek P; Jacobsson LTH; Askling J; Neovius M;
Ann Rheum Dis; 2017 Jul; 76(7):1245-1252. PubMed ID: 28073801
[TBL] [Abstract][Full Text] [Related]
5. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1108-15. PubMed ID: 22422731
[TBL] [Abstract][Full Text] [Related]
6. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
7. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register.
Kay LJ; Griffiths ID;
Rheumatology (Oxford); 2006 Nov; 45(11):1376-9. PubMed ID: 17040892
[TBL] [Abstract][Full Text] [Related]
8. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Hyrich KL; Watson KD; Lunt M; ; Symmons DP;
Ann Rheum Dis; 2010 Jun; 69(6):1086-91. PubMed ID: 20444754
[TBL] [Abstract][Full Text] [Related]
9. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
[TBL] [Abstract][Full Text] [Related]
10. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
[TBL] [Abstract][Full Text] [Related]
12. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
13. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
[TBL] [Abstract][Full Text] [Related]
14. Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity.
Pan Y; Norton S; Gwinnutt JM; Kearsley-Fleet L; Symmons DPM; Lunt M; Young A; ; Hyrich KL; Verstappen SMM
PLoS One; 2019; 14(5):e0215999. PubMed ID: 31107887
[TBL] [Abstract][Full Text] [Related]
15. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Mercer LK; Galloway JB; Lunt M; Davies R; Low AL; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL
Ann Rheum Dis; 2017 Mar; 76(3):497-503. PubMed ID: 27502891
[TBL] [Abstract][Full Text] [Related]
16. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
17. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
Harrison MJ; Dixon WG; Watson KD; King Y; Groves R; Hyrich KL; Symmons DP; ;
Ann Rheum Dis; 2009 Feb; 68(2):209-15. PubMed ID: 18385277
[TBL] [Abstract][Full Text] [Related]
18. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
19. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study.
Saraux A; Benichou J; Guillevin L; Idbrik L; Job-Deslandre C; Sibilia J; Soudant M; Wendling D; Guillemin F
Clin Exp Rheumatol; 2015; 33(5):602-10. PubMed ID: 26315585
[TBL] [Abstract][Full Text] [Related]
20. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]